Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion.
A key reason for this activity is the upcoming patent cliff. This is the period when a drug loses its exclusive status and can face biosimilar competition. Analysts are forecasting that the industry faces a $300 billion patent cliff by 2030.
